Quick Answer
Unicycive Therapeutics, Inc. reported Shares Outstanding of 22.11 million shares for fiscal year 2025.
Unicycive Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 22.11M | +94.3% |
| 2024 | 11.38M | -67.2% |
| 2023 | 34.76M | +128.2% |
| 2022 | 15.23M | +1.6% |
| 2021 | 15.00M | +76.1% |
| 2020 | 8.51M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 20.85M | -78.7% | +47.8% |
| June 30, 2025 | 14.11M | -67.6% | -88.2% |
| March 31, 2025 | 119.75M | +218.4% | +951.9% |
| December 31, 2024 | 11.38M | -67.2% | -88.4% |
| September 30, 2024 | 97.86M | +181.6% | +124.6% |
| June 30, 2024 | 43.57M | +186.0% | +15.9% |
| March 31, 2024 | 37.61M | +146.9% | +8.2% |
| December 31, 2023 | 34.76M | +128.2% | +0.0% |
- Unicycive Therapeutics, Inc. showed an increase of +94.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Unicycive Therapeutics, Inc.’s shares outstanding has grown by 159.7% (from 8.51 million shares to 22.11 million shares).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: